• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用基于人群的监测系统定义镰状细胞病死亡率,2004年至2008年

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

作者信息

Paulukonis Susan T, Eckman James R, Snyder Angela B, Hagar Ward, Feuchtbaum Lisa B, Zhou Mei, Grant Althea M, Hulihan Mary M

机构信息

Public Health Institute, Oakland, CA.

Emory University, Atlanta, GA.

出版信息

Public Health Rep. 2016 Mar-Apr;131(2):367-75. doi: 10.1177/003335491613100221.

DOI:10.1177/003335491613100221
PMID:26957672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4765986/
Abstract

OBJECTIVE

Population-based surveillance data from California and Georgia for years 2004 through 2008 were linked to state death record files to determine the all-cause death rate among 12,143 patients identified with sickle cell disease (SCD).

METHODS

All-cause death rates, by age, among these SCD patients were compared with all-cause death rates among both African Americans and the total population in the two states. All-cause death rates were also compared with death rates for SCD derived from publicly available death records: the compressed mortality files and multiple cause of death files.

RESULTS

Of 12,143 patients identified with SCD, 615 patients died. The all-cause mortality rate for the SCD population was lower than the all-cause mortality rate among African Americans and similar to the total population all-cause mortality rates from birth through age 4 years, but the rate was higher among those with SCD than both the African American and total population rates from ages 5 through 74 years. The count of deceased patients identified by using population-based surveillance data (n=615) was more than twice as high as the count identified in compressed mortality files using SCD as the underlying cause of death alone (n=297).

CONCLUSION

Accurate assessment of all-cause mortality and age at death requires long-term surveillance via population-based registries of patients with accurately diagnosed SCD.

摘要

目的

将2004年至2008年加利福尼亚州和佐治亚州基于人群的监测数据与州死亡记录档案相链接,以确定12143例确诊为镰状细胞病(SCD)患者的全因死亡率。

方法

将这些SCD患者按年龄分组的全因死亡率与这两个州非裔美国人及总人口的全因死亡率进行比较。全因死亡率还与从公开可得的死亡记录(压缩死亡率档案和多死因档案)得出的SCD死亡率进行比较。

结果

在12143例确诊为SCD的患者中,615例死亡。SCD人群的全因死亡率低于非裔美国人的全因死亡率,在出生至4岁年龄段与总人口的全因死亡率相似,但在5至74岁年龄段,SCD患者的死亡率高于非裔美国人和总人口的死亡率。使用基于人群的监测数据确定的死亡患者数(n = 615)比仅将SCD作为根本死因在压缩死亡率档案中确定的患者数(n = 297)高出两倍多。

结论

准确评估全因死亡率和死亡年龄需要通过基于人群的登记系统对确诊SCD患者进行长期监测。

相似文献

1
Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.利用基于人群的监测系统定义镰状细胞病死亡率,2004年至2008年
Public Health Rep. 2016 Mar-Apr;131(2):367-75. doi: 10.1177/003335491613100221.
2
Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.镰状细胞病监测 - 镰状细胞数据收集项目,两个州,2004-2018 年。
MMWR Surveill Summ. 2022 Oct 7;71(9):1-18. doi: 10.15585/mmwr.ss7109a1.
3
Population estimates of sickle cell disease in the U.S.美国镰状细胞病的人口估计数
Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21. doi: 10.1016/j.amepre.2009.12.022.
4
Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002.1983 - 2002年美国儿童镰状细胞病相关死亡率的趋势
J Pediatr. 2009 Apr;154(4):541-5. doi: 10.1016/j.jpeds.2008.09.052. Epub 2008 Nov 22.
5
Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH).镰状细胞病的基于人群的监测:来自加利福尼亚血红蛋白病登记与监测系统项目(RuSH)的方法、发现及启示
Pediatr Blood Cancer. 2014 Dec;61(12):2271-6. doi: 10.1002/pbc.25208. Epub 2014 Aug 30.
6
Mortality of New York children with sickle cell disease identified through newborn screening.通过新生儿筛查确诊的纽约镰状细胞病患儿的死亡率
Genet Med. 2015 Jun;17(6):452-9. doi: 10.1038/gim.2014.123. Epub 2014 Sep 25.
7
Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program.通过新生儿筛查项目诊断出的镰状细胞病患儿的死亡率特征
J Pediatr (Rio J). 2015 May-Jun;91(3):242-7. doi: 10.1016/j.jped.2014.08.006. Epub 2014 Nov 6.
8
Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.镰状细胞病的死亡率和死亡年龄:美国,1979-2005 年。
Public Health Rep. 2013 Mar-Apr;128(2):110-6. doi: 10.1177/003335491312800206.
9
Medical care utilization and mortality in sickle cell disease: a population-based study.镰状细胞病的医疗服务利用与死亡率:一项基于人群的研究。
Am J Hematol. 2005 Dec;80(4):262-70. doi: 10.1002/ajh.20485.
10
National trends in the mortality of children with sickle cell disease, 1968 through 1992.1968年至1992年镰状细胞病患儿的全国死亡率趋势
Am J Public Health. 1997 Aug;87(8):1317-22. doi: 10.2105/ajph.87.8.1317.

引用本文的文献

1
Determinants of knowledge, attitudes, and practice towards sickle cell disease in Alebtong district, Lango region, Northern Uganda.乌干达北部兰戈地区阿莱布通区对镰状细胞病的知识、态度和行为的决定因素
BMC Public Health. 2025 Mar 7;25(1):910. doi: 10.1186/s12889-025-22042-6.
2
Training young adults as community health workers specializing in pediatric to adult health care transition to support emerging adults with sickle cell disease.培训年轻人成为专门从事儿科到成人医疗保健过渡的社区卫生工作者,以支持患有镰状细胞病的新兴成年人。
Health Care Transit. 2024 Feb 19;2:100050. doi: 10.1016/j.hctj.2024.100050. eCollection 2024.
3
Evolution of an epidemic: Understanding the opioid epidemic in the United States and the impact of the COVID-19 pandemic on opioid-related mortality.疫情演变:了解美国的阿片类药物流行情况以及 COVID-19 大流行对阿片类药物相关死亡率的影响。
PLoS One. 2024 Jul 9;19(7):e0306395. doi: 10.1371/journal.pone.0306395. eCollection 2024.
4
Costs and impact of disease in adults with sickle cell disease: a pilot study.镰状细胞病成人患者的疾病成本和影响:一项试点研究。
Blood Adv. 2024 Jul 23;8(14):3629-3638. doi: 10.1182/bloodadvances.2023012477.
5
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.镰状细胞病成人死亡率:镰状细胞病实施联合会(SCDIC)登记处的结果。
Am J Hematol. 2024 May;99(5):900-909. doi: 10.1002/ajh.27279. Epub 2024 Mar 7.
6
Euvolemic automated transfusion to treat severe anemia in sickle cell disease patients at risk of circulatory overload.Euvolemic 自动输血治疗镰状细胞病患者伴循环超负荷风险的严重贫血。
Transfusion. 2024 Jan;64(1):124-131. doi: 10.1111/trf.17613. Epub 2023 Dec 8.
7
Estimating mortality in rare diseases using a population-based registry, 2002 through 2019.利用基于人群的登记处估算 2002 年至 2019 年罕见病的死亡率。
Orphanet J Rare Dis. 2023 Nov 17;18(1):362. doi: 10.1186/s13023-023-02944-7.
8
Preimplantation genetic testing for sickle cell disease: a cost-effectiveness analysis.镰状细胞病的植入前基因检测:一项成本效益分析。
F S Rep. 2023 Jun 13;4(3):300-307. doi: 10.1016/j.xfre.2023.06.001. eCollection 2023 Sep.
9
Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection.系统文献综述显示镰状细胞病和镰状细胞性状的全球患病率及出生患病率数据存在差距:呼吁采取行动扩大并统一数据收集工作。
J Clin Med. 2023 Aug 25;12(17):5538. doi: 10.3390/jcm12175538.
10
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.全球、区域和国家镰状细胞病的患病率和死亡负担,2000-2021 年:2021 年全球疾病负担研究的系统分析。
Lancet Haematol. 2023 Aug;10(8):e585-e599. doi: 10.1016/S2352-3026(23)00118-7. Epub 2023 Jun 15.

本文引用的文献

1
Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH).镰状细胞病的基于人群的监测:来自加利福尼亚血红蛋白病登记与监测系统项目(RuSH)的方法、发现及启示
Pediatr Blood Cancer. 2014 Dec;61(12):2271-6. doi: 10.1002/pbc.25208. Epub 2014 Aug 30.
2
State-based surveillance for selected hemoglobinopathies.针对特定血红蛋白病的基于状态的监测。
Genet Med. 2015 Feb;17(2):125-30. doi: 10.1038/gim.2014.81. Epub 2014 Jul 3.
3
United States life tables eliminating certain causes of death, 1999-2001.1999 - 2001年美国去除某些死因后的生命表
Natl Vital Stat Rep. 2013 May 31;61(9):1-128.
4
Identifying sickle cell disease cases using administrative claims.使用行政索赔识别镰状细胞病病例。
Acad Pediatr. 2014 Sep-Oct;14(5 Suppl):S61-7. doi: 10.1016/j.acap.2014.02.008. Epub 2014 May 29.
5
Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil.巴西里约热内卢的血红蛋白病新生儿筛查计划。
Pediatr Blood Cancer. 2014 Jan;61(1):34-9. doi: 10.1002/pbc.24711. Epub 2013 Sep 4.
6
Sickle cell disease related mortality in the United States (1999-2009).美国镰状细胞病相关死亡率(1999-2009 年)。
Pediatr Blood Cancer. 2013 Sep;60(9):1482-6. doi: 10.1002/pbc.24557. Epub 2013 Apr 23.
7
Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.镰状细胞病的死亡率和死亡年龄:美国,1979-2005 年。
Public Health Rep. 2013 Mar-Apr;128(2):110-6. doi: 10.1177/003335491312800206.
8
Population estimates of sickle cell disease in the U.S.美国镰状细胞病的人口估计数
Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21. doi: 10.1016/j.amepre.2009.12.022.
9
Improved survival of children and adolescents with sickle cell disease.镰状细胞病患儿和青少年生存率提高。
Blood. 2010 Apr 29;115(17):3447-52. doi: 10.1182/blood-2009-07-233700. Epub 2010 Mar 1.
10
Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.生活在英格兰的镰状细胞病患儿的临床结局:东伦敦的一个新生儿队列研究
Haematologica. 2007 Jul;92(7):905-12. doi: 10.3324/haematol.10937.